Biodexa Pharmaceuticals PLC shareholders approved a one-for-10,000 reverse stock split effective July 30, 2026, reducing the number of ordinary shares outstanding to 51,453,281. Concurrently, the ADS ratio adjusted from 500,000:1 to 50:1, maintaining proportional ownership and leaving the ADS count at 1,029,063. The company also received authority to allot up to £25,000,000 in new shares through 2029 and adopted new articles of association. Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company developing innovative treatments for gastrointestinal cancers and other diseases.

Biodexa Pharmaceuticals PLC entered into a securities purchase agreement on June 29, 2026, for a registered direct offering and a concurrent private placement, alongside a warrant inducement. The transactions, expected to close on July 1, 2026, are expected to generate approximately $3.54 million in gross proceeds. The company is a pharmaceutical company focused on developing and commercializing therapeutic products.